Angela Brown, MD
Cardiovascular Disease · Saint Louis, MONPI 1982622403
Payments from drug & device makers
Across 38 payments — averaging $553.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Recor Medical Inc$11K
- Medtronic$10K
- Astellas Pharma US Inc$124
- AstraZeneca$40
- AbbVie$25
What the payments were for
- Consulting fees$14,62570%
- Speaking & faculty fees$1,5007%
- Travel & lodging$3,55717%
- Food & beverage$1,3556%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Recor Medical Inc | 23 | $11,284 |
| Medtronic | 12 | $9,564 |
| Astellas Pharma US Inc | 1 | $124 |
| AstraZeneca | 1 | $40 |
| AbbVie | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,037 in reported general payments places this provider in the 80th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $70,681 |
| XareltoRivaroxaban | 12 | $7,027 |
| EdarbiAzilsartan Medoxomil | 12 | $6,862 |
| Isradipine | 34 | $5,238 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 54 | $2,246 |
| Amlodipine Besylate | 311 | $1,695 |
| Atorvastatin Calcium | 134 | $1,194 |
| Valsartan | 31 | $1,147 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 25 | $1,097 |
| Potassium Chloride | 44 | $1,053 |
| Spironolactone | 145 | $1,036 |
| Nebivolol Hcl | 11 | $938 |
| Losartan Potassium | 96 | $935 |
| Doxazosin Mesylate | 92 | $806 |
| Carvedilol | 133 | $788 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Saint Louis
- Mohammad TahirSaint Louis$2.7M
- Joshua MitchellSaint Louis$1.4M
- Nathan StitzielSaint Louis$1.2M
- Daniel KellySaint Louis$1.1M
- Georges ChahoudSaint Louis$967K
- Jiafu OuSaint Louis$853K
- William BowenSaint Louis$726K
- Mustafa HusainiSaint Louis$465K
- Denise JanosikSaint Louis$295K
- Farhan KatchiSaint Louis$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.